Of note, a CD276-CAR expressing an antigen-binding domain derived from Enoblituzumab (MGA271), a humanized antibody from MacroGenics recognizing an epitope of CD276 with high tumor reactivity, was particularly effective against pediatric osteosarcoma, Ewing sarcoma and medulloblastoma [36], but has not been tested for RMS in vitro, nor in vivo. This evidence concerns the gene CD276 and neoplasm.